C-Path’s TRxA announces $250,000 grant for drug development project on antibiotic-resistant gram-negative bacteria
C-Path’s Translational Therapeutics Accelerator (TRxA) has announced that Kenneth Keiler, Ph.D. has been awarded a research grant for his project titled ’Inhibitors of the Gram-negative Cell Envelope Stress Response as Anti-Infectives and Antibiotics’.
Registered users, subscribers or members - SIGN IN
To continue reading this article
Membership
Included as a benefit
Members of Applied Microbiology International have unlimited access to The Microbiologist as a benefit of membership. Just sign in with your usual membership credentials.
Find out more about how to join.
Register
FREE
Want to read more before deciding on a subscription? It only takes a minute to sign up for a free account and you’ll get to enjoy more free content each month.
Subscribe
3.75 per month / £35 annually
Get unlimited access to The Microbiologist.